ES2659577T3 - Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina - Google Patents

Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina Download PDF

Info

Publication number
ES2659577T3
ES2659577T3 ES05793645.2T ES05793645T ES2659577T3 ES 2659577 T3 ES2659577 T3 ES 2659577T3 ES 05793645 T ES05793645 T ES 05793645T ES 2659577 T3 ES2659577 T3 ES 2659577T3
Authority
ES
Spain
Prior art keywords
formula
added
compound
ipa
naoh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05793645.2T
Other languages
English (en)
Inventor
Donald R. Gauthier
Richard Desmond
Paul N. Devine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Application granted granted Critical
Publication of ES2659577T3 publication Critical patent/ES2659577T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un proceso para preparar un compuesto de fórmula I: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo, que comprende: oxidar un sulfuro de fórmula II: **(Ver fórmula)** con un agente catalizador de la oxidación y un oxidante; para dar un compuesto de fórmula III: **(Ver fórmula)** seguido por la reducción catalítica del compuesto de fórmula III; para dar el compuesto de fórmula I:: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
Sulfona-alqueno
247,41 (teórico= 3,17 kg)
Se hizo una lechada del alcohol en tolueno y se agregó ácido sulfúrico. Se calentó la reacción a reflujo entre 1 y 2 horas con separación azeotrópica de agua. Al finalizar, la reacción se enfrió a 70 °C y se agregó agua. La reacción se enfrió a RT y se separaron las fases. Se agregó tolueno (6 L/kg) y NaOH 5 N (2 eq., 1,6 L/kg,
5 pH>9) a la fase acuosa manteniendo la temperatura a < 30 °C. Se separaron las fases y se trató la fase orgánica con ácido sulfúrico 1 N (1 eq. de H2SO4, ~8 L/kg, pH~1). Se separaron las fases y se transfirió la fase acuosa directamente a la reacción de oxidación.
EJEMPLO 3
imagen7
Materiales
PM Cantidad Moles Densidad
Sulfuro-alqueno
247,41 3,30 kg 13,34
Na2WO4 x H2O
329,85 43,9 g 0,133
H2O2 al 30%
34,01 3,78 kg (3,41 L) 33,35 1,110
NaOH 5 N (1,5 ml/g Teórico)
5,6 L 12,0
NaOH 1 N
5,6 L
Solución salina al 20%
5,6 L
Tolueno (5 ml/g Teórico)
19 L
n-hetano
22,4 L
Sulfona-alqueno
279,41 (Teórico: 3,73 kg) 13,34
Na2SO3
126,04 0,84 kg 6,67
10
A una solución de sulfuro-alqueno en H2SO4 acuoso se agregó Na2WO4 x 2H2O. H2O2 (30%) se agregó en un periodo entre de 0,5 y 1 h manteniendo la temperatura por debajo de 55 °C. La mezcla resultante se dej ó asentar entre 50 y 55 °C hasta que el intermediario de sulfóxido alcance una cantidad de <0,5 A% (entre 1 y 2 h). La mezcla resultante se enfrió a 10 °C y se agr egó tolueno (5 L/kg) seguido por NaOH 5 N manteniendo la 15 temperatura interna <30 °C. Se separó la fase acuos a y se lavó la capa de tolueno con NaOH 1 N, seguido por un lavado con solución salina al 20%. La capa de tolueno típicamente da entre 85 y 90% de rendimiento. La reacción se concentró a 3 ml/g de volumen total (10 L) tiempo durante el cual cristalizó la sulfona-alqueno a partir de la solución. Se entibió la solución a entre 50 y 55 °C y se agregó heptano (3 mL/g) mantenie ndo la temperatura interna entre 50 y 55 °C. A la solución resultante se agregó más heptano (3 ml/g) a una
8
temperatura entre 50 y 55 °C en 1 hora. La lechada resultante se enfrió a 23 °C en un periodo de entre 0,5 y 1h, se dejó asentar durante 0,5 h y se filtró a temperatura ambiente. La torta del filtro se lavó con 1:3 tolueno/heptano (4 mL/g, 12 L) y luego se secó a 50 °C al vacío con una purga d e N2. El rendimiento típico fue entre 75 y 80 %, con >99 % en peso y 99 A% de pureza. Sobre las fases acuosas combinadas (capa acuosa después de NaOH 5 N, después de lavar con NaOH 1 N, después de lavar con solución salina al 20%) a 23 °C se agregó Na2SO3 sólido hasta que la prueba de peróxidos dio negativa mediante tiras reactivas Quantofix. Se registra una exoterma de ~3 °C.
EJEMPLO 4
en
Materiales
PM Cantidad Moles Densidad
Sulfona-alqueno
279,41 3,00 kg 10,74
Pd/C al 10%
600 g
HCO2H
46,02 2,47 kg (2,03 L) 53,68 (5 eq.) 1,22
IPA
15 L
H2O
6 L
Base libre
281,41 (Teórico = 3,02 kg) 10,74
NaOH 5 N
7,5 L 37,58 (3,5 eq.)
MTBE (10 ml/g)
30 L
H2O (3 ml/g)
9,0 L
HCl 5N en IPA
2,58 L 12,88 (1,2 eq.)
IPA (9,2 mL/g)
27,6 L
sal de HCl
317,88 (Teórico = 3,41 kg) 10,74
10
Se agregó HCO2H (5 eq.) a una lechada de sulfona-alqueno en IPA. A la solución resultante se agregó una suspensión de Pd/C al 10% en agua (5 ml/g). Se dejó asentar la suspensión a RT entre 16 y 24 h hasta que la sulfona-alqueno fue <0,10 A%. Se filtró el lote a través de una almohadilla de solka floc y se lavó la torta del filtro con 1:1 IPA/agua (2 mL/g). El ensayo típico de la combinación de filtrado y lavado tuvo entre 95 y 98 % de 15 rendimiento. Se transfirió el filtrado a un recipiente de extracción de 100 L conteniendo NaOH 5 N y MTBE preenfriado a 15 °C. Se separó la fase acuosa y se lavó la fase de MTBE con H2O (3 mL/g). La capa de MTBE se concentró a 4 ml/g de volumen total (12 L), se lavó rápidamente con IPA (2 x 5 ml/g) para eliminar el MTBE y el agua, luego se diluyó a 9 ml/g en IPA (contenido de H2O típico de entre 0,5 y 1%). Se entibió el filtrado a 65 °C y se agregó HCl 5 N en IPA. La lechada result ante se calentó a entre 75 y 80 °C hasta que todos los 20 sólidos estén disueltos. Se enfrió lentamente la solución se le agregó sal de HCl pura a entre 65 y 70 °C. Se
9
dejó asentar la lechada a entre 65 y 70 °C durante 1 hora y luego se enfrió lentamente a 23 °C en 1 h. Se filtró la lechada, se lavó con IPA (3 ml/g), y se secó sobre N2.
10

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES05793645.2T 2004-10-13 2005-10-13 Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina Expired - Lifetime ES2659577T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61819604P 2004-10-13 2004-10-13
US618196P 2004-10-13
PCT/EP2005/011020 WO2006040155A1 (en) 2004-10-13 2005-10-13 Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine

Publications (1)

Publication Number Publication Date
ES2659577T3 true ES2659577T3 (es) 2018-03-16

Family

ID=35478927

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05793645.2T Expired - Lifetime ES2659577T3 (es) 2004-10-13 2005-10-13 Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina

Country Status (14)

Country Link
US (1) US7923459B2 (es)
EP (1) EP1802573B1 (es)
JP (1) JP4891908B2 (es)
KR (1) KR101319235B1 (es)
CN (1) CN101056854B (es)
AU (1) AU2005293754B2 (es)
CA (1) CA2584831C (es)
DK (1) DK1802573T3 (es)
ES (1) ES2659577T3 (es)
HU (1) HUE029790T2 (es)
MX (1) MX2007004215A (es)
NZ (1) NZ555094A (es)
PL (1) PL1802573T3 (es)
WO (1) WO2006040155A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
MXPA06013941A (es) 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
MX2007004216A (es) * 2004-10-13 2007-10-10 Neurosearch Sweden Ab Proceso para la sintesis de 4-(3-sulfonil)-piperidinas.
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
MX2009011020A (es) * 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX343620B (es) * 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) * 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
AR105434A1 (es) * 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
EP3357909A1 (en) 2017-02-02 2018-08-08 Sandoz AG Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
JP2020532517A (ja) 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
EP4741013A3 (en) 2020-02-13 2026-08-05 Prilenia Neurotherapeutics Ltd. Combination therapy for treating amyotrophic lateral sclerosis using pridopidine and another active agent
CN116472043A (zh) 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
CA3250337A1 (en) 2022-05-03 2023-11-09 Prilenia Neurotherapeutics Ltd. METHODS AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE
IL315049A (en) 2024-08-15 2026-03-01 Prilenia Neurotherapeutics Ltd Taste-masked pridopidine formulations, method of use thereof and process for preparation thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (es) 1964-04-14
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
FR1459013A (fr) 1964-08-05 1966-04-29 Allen & Hanburys Ltd Procédé de préparation de dérivés de la 4-phényl-pipéridine
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US4048314A (en) 1974-12-17 1977-09-13 Delmar Chemicals Limited Morpholino containing 4-arylpiperidine derivatives
GB1560271A (en) 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
US4202898A (en) 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
FR2459797A2 (fr) 1978-08-01 1981-01-16 Synthelabo Derives de phenyl-1 piperazine et leur application en therapeutique
US4333942A (en) 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
US4518712A (en) 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
US4485109A (en) 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
ATE50987T1 (de) 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
US4504660A (en) 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DK0641320T3 (da) 1991-04-17 2001-08-20 Upjohn Co Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
EP0867183B1 (en) * 1996-07-22 2004-10-06 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinol and arylpiperidine derivatives and drugs containing the same
US5892041A (en) 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
BR0011823A (pt) 1999-06-22 2002-03-19 Neurosearch As Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
EP1313477A4 (en) 2000-07-15 2004-03-03 Smithkline Beecham Corp COMPILATIONS AND METHODS
JP2004523530A (ja) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CA2569843A1 (en) 2004-06-08 2005-12-22 A. Carlsson Research Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7884104B2 (en) 2004-10-01 2011-02-08 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
MX2007004216A (es) 2004-10-13 2007-10-10 Neurosearch Sweden Ab Proceso para la sintesis de 4-(3-sulfonil)-piperidinas.
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007065655A1 (en) 2005-12-07 2007-06-14 Neurosearch Sweden Ab Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission

Also Published As

Publication number Publication date
KR20070065911A (ko) 2007-06-25
KR101319235B1 (ko) 2013-10-16
CN101056854B (zh) 2013-06-05
US20070238879A1 (en) 2007-10-11
PL1802573T3 (pl) 2017-03-31
MX2007004215A (es) 2007-12-12
CN101056854A (zh) 2007-10-17
DK1802573T3 (en) 2016-12-19
JP2008515951A (ja) 2008-05-15
JP4891908B2 (ja) 2012-03-07
NZ555094A (en) 2009-07-31
EP1802573A1 (en) 2007-07-04
EP1802573B1 (en) 2016-09-28
HUE029790T2 (hu) 2017-04-28
AU2005293754A1 (en) 2006-04-20
US7923459B2 (en) 2011-04-12
HK1105195A1 (zh) 2008-02-06
CA2584831A1 (en) 2006-04-20
AU2005293754B2 (en) 2011-07-21
CA2584831C (en) 2013-09-17
WO2006040155A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
JP4795435B2 (ja) エソメプラゾール及びその塩の製造方法
CN112047888B (zh) 一种合成恩杂鲁胺的方法
JP2019194203A (ja) フェブキソスタットの調製のための新規方法
SU629881A3 (ru) Способ получени производных тиазоло (3,4 - ) изохинолина или их оптических изомеров или их солей
ES2320172T3 (es) Procedimiento para la produccion de 5-(4-(4-(5-ciano-3-indolil)-butil)-1-piperazinil)-benzofuran-2-carboxamida.
EP1501824A1 (en) A method for the purification of lansoprazole
JP4485192B2 (ja) トロペノールの工業的製造方法
CN115260118A (zh) 一种dntf的制备方法
US4076728A (en) Process for manufacturing crystal violet lactone
ES2356501T3 (es) Procedimiento para la preparación de zolmitriptan.
CN110526913A (zh) 一种抗凝药物阿哌沙班相关物质的制备方法
WO2022152078A1 (zh) 一种西酞普兰或s-西酞普兰的纯化方法
CN102108049A (zh) 9-芴甲酸的制备方法
CN116239461B (zh) 一种苯甲酸类化合物的合成工艺
CN112239422B (zh) 一种布格替尼中间体、其盐、其制备方法以及布格替尼的制备方法
JP5751177B2 (ja) ルテニウム含有化合物及びその製造方法
CN110407718B (zh) 以三苯胺为给体的苯甲酰亚胺类衍生物及其制备与应用
US10696633B2 (en) Process for the preparation of fexofenadine and of intermediates used therein
CN114989046A (zh) 一种达伯西汀氧化杂质的合成方法
KR20250007301A (ko) 고순도의 무정형 테고프라잔 제조방법
CN109553544B (zh) 一种双氯芬酸钠的合成方法
US2868804A (en) Betaine ascorbate
CN107892666B (zh) 一种5-苯基吡咯衍生物及其制备方法和用途
CN113861131A (zh) 一种西替利嗪杂质c的制备方法
CN104072403A (zh) 一种制备化合物unc1215的方法